Partnering is central to Oasmia’s strategy to build a sustainable global oncology business. This is demonstrated by Oasmia’s global licensing agreements with Elevar Therapeutics for the company’s lead cancer therapy Apealea® (paclitaxel micellar) and Kazia Therapeutics for the development stage program Cantrixil.

Oasmia is actively seeking opportunities to acquire and license novel product opportunities in areas of significant medical need. Oasmia is primarily seeking to acquire or license global development and commercialization rights to oncology programs in early clinical development stage, but is also interested in late stage pre-clinical stage projects with promising science.